Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection microbiologystudy
Antimicrobial Agents and Chemotherapy, Volume 68, Issue 7, July 2024. Source link